Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer

Immune gene expression and response to chemotherapy in advanced breast cancer

(2018) Theodoros Foukakis et al.   BRITISH JOURNAL OF CANCER

Effect of macrophages on breast cancer cell proliferation, and on expression of hormone receptors, uPAR and HER-2

(2017) Therése Lindsten et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

(2017) Matthew J. Ellis et al.   JOURNAL OF CLINICAL ONCOLOGY

CDK4/6 inhibition triggers anti-tumour immunity

(2017) Shom Goel et al.   NATURE

Prognostic value of tumor-infiltrating Foxp3+ regulatory T cells in patients with breast cancer: a meta-analysis

(2017) Yu Zhou et al.   Journal of Cancer

Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes

(2016) Sasha E. Stanton et al.   JAMA Oncology

Evaluation of tumor-infiltrating lymphocytes in breast cancer; proposal of a simpler method

(2015) A. I. Hida et al.   ANNALS OF ONCOLOGY

Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States

(2015) Sarah S. Mougalian et al.   CANCER

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

(2015) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

(2014) M. V. Dieci et al.   ANNALS OF ONCOLOGY

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

(2014) R. Salgado et al.   ANNALS OF ONCOLOGY

The Value of Tumor Infiltrating Lymphocytes (TILs) for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis

(2014) Yan Mao et al.   PLoS One

Construction of novel immune-related signature for prediction of pathological complete response to neoadjuvant chemotherapy in human breast cancer

(2013) Y. Sota et al.   ANNALS OF ONCOLOGY

Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial

(2013) Yasmin Issa-Nummer et al.   PLoS One

Gene expression profiling in breast cancer: classification, prognostication, and prediction

(2011) Jorge S Reis-Filho et al.   LANCET

Gene-Expression Signatures in Breast Cancer

(2009) Christos Sotiriou et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

(2008) C. Desmedt et al.   CLINICAL CANCER RESEARCH

Neoadjuvant Vinorelbine-Capecitabine Versus Docetaxel-Doxorubicin-Cyclophosphamide in Early Nonresponsive Breast Cancer: Phase III Randomized GeparTrio Trial

(2008) G. von Minckwitz et al.   JNCI-Journal of the National Cancer Institute